527 related articles for article (PubMed ID: 10554045)
21. In vitro compatibility of tazarotene with other topical treatments of psoriasis.
Hecker D; Worsley J; Yueh G; Lebwohl M
J Am Acad Dermatol; 2000 Jun; 42(6):1008-11. PubMed ID: 10827404
[TBL] [Abstract][Full Text] [Related]
22. Tazarotene foam, 0.1%, for the treatment of acne.
Smith JA; Narahari S; Hill D; Feldman SR
Expert Opin Drug Saf; 2016 Jan; 15(1):99-103. PubMed ID: 26560170
[TBL] [Abstract][Full Text] [Related]
23. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.
Lebwohl M; Ast E; Callen JP; Cullen SI; Hong SR; Kulp-Shorten CL; Lowe NJ; Phillips TJ; Rosen T; Wolf DI; Quell JM; Sefton J; Lue JC; Gibson JR; Chandraratna RA
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):705-11. PubMed ID: 9591815
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.
Thiboutot D; Arsonnaud S; Soto P
J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s3-10. PubMed ID: 18575220
[TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy and safety of tazarotene: optimizing clinical results.
Lebwohl M
Cutis; 1998 Feb; 61(2 Suppl):27-9. PubMed ID: 9787989
[TBL] [Abstract][Full Text] [Related]
26. Determination of clobetasol propionate, tazarotene and tazarotenic acid in Bama mini-pig skin by UPLC-MS/MS: Application to pharmacokinetic and drug-drug interaction studies.
Lu YT; Guan R; Zheng JR; Hang TJ; Song M
J Pharm Biomed Anal; 2020 Jul; 186():113322. PubMed ID: 32380355
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of topical tazarotene in the treatment of mild to moderate acne.
Leyden JJ
Cutis; 2004 Oct; 74(4 Suppl):9-15. PubMed ID: 15543714
[TBL] [Abstract][Full Text] [Related]
28. Optimizing treatment with topical tazarotene.
Guenther LC
Am J Clin Dermatol; 2003; 4(3):197-202. PubMed ID: 12627995
[TBL] [Abstract][Full Text] [Related]
29. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect.
Weinstein GD; Krueger GG; Lowe NJ; Duvic M; Friedman DJ; Jegasothy BV; Jorizzo JL; Shmunes E; Tschen EH; Lew-Kaya DA; Lue JC; Sefton J; Gibson JR; Chandraratna RA
J Am Acad Dermatol; 1997 Jul; 37(1):85-92. PubMed ID: 9216528
[TBL] [Abstract][Full Text] [Related]
30. [Medication of the month. Tazarotene 0.05%-0.1% (Zorac)].
Henno A; Hua MT; de la Brassinne M
Rev Med Liege; 2003 Nov; 58(11):706-8. PubMed ID: 14748200
[TBL] [Abstract][Full Text] [Related]
31. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis.
Krueger GG; Drake LA; Elias PM; Lowe NJ; Guzzo C; Weinstein GD; Lew-Kaya DA; Lue JC; Sefton J; Chandraratna RA
Arch Dermatol; 1998 Jan; 134(1):57-60. PubMed ID: 9449910
[TBL] [Abstract][Full Text] [Related]
32. Acitretin : A Review of its Pharmacology and Therapeutic Use.
Pilkington T; Brogden RN
Drugs; 1992 Apr; 43(4):597-627. PubMed ID: 28421560
[TBL] [Abstract][Full Text] [Related]
33. Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis.
Kaur I; Dogra S; Jain R; Kumar B
Indian J Dermatol Venereol Leprol; 2008; 74(5):471-4. PubMed ID: 19052406
[TBL] [Abstract][Full Text] [Related]
34. Short contact therapy with tazarotene in psoriasis vulgaris.
Veraldi S; Caputo R; Pacifico A; Peris K; Soda R; Chimenti S
Dermatology; 2006; 212(3):235-7. PubMed ID: 16549919
[TBL] [Abstract][Full Text] [Related]
35. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.
Shalita AR; Chalker DK; Griffith RF; Herbert AA; Hickman JG; Maloney JM; Miller BH; Tschen EH; Chandraratna RA; Gibson JR; Lew-Kaya DA; Lue JC; Sefton J
Cutis; 1999 Jun; 63(6):349-54. PubMed ID: 10388959
[TBL] [Abstract][Full Text] [Related]
36. Topical tazarotene cream (0.1%) in the treatment of facial acne: an open clinical trial.
Zakaria AS; Paul HK; Rahman MA; Islam MT; Choudhury AM
Bangladesh Med Res Counc Bull; 2010 Aug; 36(2):43-6. PubMed ID: 21473199
[TBL] [Abstract][Full Text] [Related]
37. The only topical retinoid without a generic alternative: tazarotene.
Kircik LH
J Drugs Dermatol; 2013 Mar; 12(3):s52. PubMed ID: 23545934
[No Abstract] [Full Text] [Related]
38. Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy.
Tanghetti E; Lebwohl M; Stein Gold L
J Drugs Dermatol; 2018 Dec; 17(12):1280-1287. PubMed ID: 30586259
[TBL] [Abstract][Full Text] [Related]
39. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
Weinstein GD; Koo JY; Krueger GG; Lebwohl MG; Lowe NJ; Menter MA; Lew-Kaya DA; Sefton J; Gibson JR; Walker PS;
J Am Acad Dermatol; 2003 May; 48(5):760-7. PubMed ID: 12734506
[TBL] [Abstract][Full Text] [Related]
40. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
Tanghetti E; Dhawan S; Green L; Ling M; Downie J; Germain MA; Kasteler JS; Kircik L; Oefelein MG; Draelos Z
J Drugs Dermatol; 2011 Jul; 10(7):783-92. PubMed ID: 21720661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
